Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial of epacadostat for women who have a raised level of CA125 after treatment for ovarian, primary peritoneal or fallopian tube cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
More about this trial
The usual treatment for ovarian cancer is chemotherapy. Having no signs of cancer afterwards, means that there has been a complete response to chemotherapy.
After treatment, women have blood tests to look for a marker called CA125. Having an increased amount of CA125 in the blood may mean that the cancer has come back. But the test isn’t completely reliable. You can have an increased level of CA125, without any other signs or symptoms of the cancer having come back.
Doctors aren’t sure if women should have more treatment if this happens and what the best treatment is. Some women might have a
In this trial, researchers looked at a drug called epacadostat (INCB024360). It is a type of targeted drug called an immunotherapy. It helps the body’s
Some women had tamoxifen and some had epacadostat. The trial compared these 2 drugs to see if epacadostat worked better than tamoxifen.
Summary of results
- 22 had epacadostat
- 20 had tamoxifen
- just under 4 months in women who had epacadostat
- just over 5.5 months in women who had tamoxifen
How to join a clinical trial
Dr Rebecca Kristeleit